TGFB1 and melanoma: For instance, improved outcomes following ICB in melanoma patients correlated with the formation of CD8+CD20+ TLS [170], while reduced tumour burden in melanoma-bearing mice following anti-TGFβ relies on rendering tumours more permissible to T cell attack by remodelling the tumour stroma [171].